Supplementary Table 1. Year-specific IgM seroprevalence of *T. gondii*, rubella virus, and CMV among pregnant women (2012–2022).

Year	Annual number tested	*Toxoplasma* IgM %; 95% CI	Rubella IgM %; 95% CI	CMV IgM %; 95% CI
2012	1191	1.7%; 1.1–2.6%	0.4%; 0.2–1.0%	0.3%; 0.1–0.9%
2013	919	0.7%; 0.3–1.4%	0.3%; 0.1–1.0%	0.1%; 0.0–0.6%
2014	1351	0.4%; 0.2–1.0%	0.1%; 0.0–0.5%	0.0%; 0.0–0.3%
2015	1206	0.7%; 0.3–1.3%	0.2%; 0.0–0.6%	0.0%; 0.0–0.3%
2016	1059	0.2%; 0.1–0.7%	0.0%; 0.0–0.4%	0.3%; 0.1–0.8%
2017	1309	0.2%; 0.0–0.6%	0.0%; 0.0–0.3%	0.2%; 0.1–0.7%
2018	2070	0.4%; 0.2–0.8%	0.2%; 0.1–0.5%	0.1%; 0.0–0.4%
2019	1938	0.8%; 0.5–1.3%	0.4%; 0.2–0.7%	0.1%; 0.0–0.4%
2020	1514	0.3%; 0.1–0.7%	0.1%; 0.0–0.5%	0.1%; 0.0–0.5%
2021	2102	0.2%; 0.1–0.5%	0.1%; 0.0–0.3%	0.0%; 0.0–0.2%
2022	2218	0.3%; 0.1–0.6%	0.0%; 0.0–0.3%	0.1%; 0.0–0.3%

Annual IgM seroprevalence of *T. gondii*, rubella virus, and CMV among pregnant women between 2012 and 2022. Data are presented as n (%) with corresponding 95% CIs. The denominator represents the annual number of women tested. Interpretation of the year-specific IgM seroprevalence estimates is limited because of the low number of positive cases in several years. *T. gondii*: *Toxoplasma gondii*; CMV: cytomegalovirus; IgM: immunoglobulin M; CI: confidence interval.

Supplementary Table 2. Year-specific IgG seroprevalence of *T. gondii*, rubella virus, and CMV among pregnant women (2012–2022).

Year	Annual number tested	*Toxoplasma* IgG %; 95% CI	Rubella IgG %; 95% CI	CMV IgG %; 95% CI
2012	1191	33.2%; 30.5–35.9%	96.6%; 95.5–97.5%	96.3%; 95.1–97.2%
2013	919	30.1%; 27.3–33.2%	99.1%; 98.3–99.6%	95.6%; 94.1–96.8%
2014	1351	25.8%; 23.5–28.2%	97.6%; 96.7–98.3%	99.8%; 99.3–99.9%
2015	1206	32.7%; 30.1–35.4%	95.8%; 94.5–96.8%	98.7%; 97.9–99.2%
2016	1059	25.6%; 23.1–28.3%	96.7%; 95.4–97.6%	96.5%; 95.2–97.5%
2017	1309	28.3%; 25.9–30.8%	98.2%; 97.3–98.8%	96.3%; 95.2–97.2%
2018	2070	33.9%; 31.9–36.0%	93.5%; 92.3–94.5%	96.7%; 95.8–97.4%
2019	1938	34.9%; 32.8–37.0%	90.3%; 88.9–91.5%	93.3%; 92.1–94.3%
2020	1514	35.1%; 32.7–37.5%	92.8%; 91.4–94.0%	97.4%; 96.5–98.1%
2021	2102	32.5%; 30.5–34.5%	94.6%; 93.5–95.5%	98.6%; 98.0–99.0%
2022	2218	30.5%; 28.6–32.4%	93.8%; 92.7–94.7%	97.3%; 96.5–97.9%

Annual IgG seroprevalence of *T. gondii*, rubella virus, and CMV among pregnant women between 2012 and 2022. Data are presented as n (%) with corresponding 95% CIs. The denominator represents the annual number of women tested. Analyses of the IgM markers were limited by the very low number of annual positive cases; several binomial models failed to converge or produced unstable estimates. Consequently, reliable annual ORs could not be estimated for the IgM markers. *T. gondii*: *Toxoplasma gondii*; CMV: cytomegalovirus; IgG, immunoglobulin G; IgM, immunoglobulin M; CI, confidence interval; OR, odds ratio.